Blog

  • BioCardia Announces CardiAMP Chronic Myocardial Ischemia

    BioCardia Announces CardiAMP Chronic Myocardial Ischemia

    SUNNYVALE, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) — BioCardia, Inc. (NASDAQ: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the primary endpoint results of the open label roll-in cohort of the CardiAMP® Cell Therapy in Chronic Myocardial Ischemia Trial.

    Results from the open label roll-in cohort patients having chronic myocardial ischemia with refractory angina show that the minimally-invasive CardiAMP Cell Therapy procedure was well tolerated with no treatment emergent major adverse cardiac events. All patients were on guideline-directed medical therapy (GDMT) and responded positively to the autologous cell therapy. Patients experienced increased exercise tolerance of an average of 80 seconds and an average of 82% reduction in angina episodes at the six-month primary endpoint when compared to measurements prior to cell therapy treatment. Sixty percent of the patients showed substantial improvements in both measures.

    These early, open-label results compare favorably to those demonstrated by current FDA approved therapies such as Ranolazine and Enhanced External Counter Pulsation (EECP) (1,2,3). Patients already on Ranolazine experienced dramatic reduction in angina episodes at the six-month follow-up. These results are in line with previous compelling investigational trial results utilizing cost prohibitive cell therapy (4). 

    “With these final roll-in results, this novel investigational therapy shows promise in addressing debilitating refractory angina, a significant unmet need for patients with chronic myocardial ischemia,” said Carl Pepine, MD, MACC, Professor of Medicine, Division of Cardiovascular Medicine, University of Florida at Gainesville.

    “We are working with our investigators to submit these results for peer reviewed scientific publication,” said Peter Altman, President and CEO. “The results from this roll-in cohort supports our continued development of this novel therapeutic approach for chronic myocardial ischemia with refractory angina and enhances the value of our CardiAMP cell therapy platform.”

    About Chronic Myocardial Ischemia with Refractory Angina

    Chronic myocardial ischemia occurs in the setting of coronary artery disease when there is reduced blood flow to the heart. This causes angina, a type of chest pain which is characterized as refractory angina when this pain cannot be controlled by a combination of optimal medical therapy, angioplasty or bypass surgery, and is estimated to impact 600,000 to 1.8 million patients in the United States. Up to 15% of patients who have ischemia or angina and undergo cardiac catheterization are suboptimal candidates for conventional revascularization. Although prognosis of refractory angina has improved in recent years, patients with refractory angina experience a significantly impaired quality of life with disproportionately high utilization of healthcare services. These observations reflect the great need for new therapies for these patients. Promising results in treating this patient population with an autologous bone marrow derived cell therapy have been shown previously (4).

    About the CardiAMP Cell Therapy Program

    Designated by the FDA as a Breakthrough Therapy for Ischemic Heart Failure, CardiAMP Cell Therapy uses a patient’s own bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure to potentially stimulate the body’s natural healing response. CardiAMP Cell Therapy incorporates three proprietary elements not previously utilized in investigational cardiac cell therapy: a pre-procedural cell analysis for patient selection, a high target dosage of cells, and a proprietary delivery system that has been shown to be safer than other intramyocardial delivery systems and exponentially more successful in cell retention. The CardiAMP cell therapy trials for the indications of both chronic myocardial ischemia and ischemic heart failure are covered by the Center for Medicare and Medicaid for both treatment and control procedures. CAUTION – Limited by United States law to investigational use. 

    About BioCardia®
    BioCardia, Inc., headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP® autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms with three cardiac clinical stage product candidates in development. These therapies are enabled by its Helix™ biotherapeutic delivery and Morph® vascular navigation product platforms, and soon the Heart3D™ fusion imaging platform. BioCardia selectively partners on biotherapeutic delivery with peers developing important biologic therapies. For more information visit www.biocardia.com.

    Reference:

    1Stone PH, Gratsiansky NA, Blokhin A, Huang IZ, Meng L; ERICA Investigators. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol. 2006 Aug 1;48(3):566-75. doi: 10.1016/j.jacc.2006.05.044. Epub 2006 Jun 15. PMID: 16875985.

    2 Sendón JL, Lee S, Cheng ML, Ben-Yehuda O; CARISA study investigators. Effects of ranolazine on exercise tolerance and angina frequency in patients with severe chronic angina receiving maximally-tolerated background therapy: analysis from the Combination Assessment of Ranolazine In Stable Angina (CARISA) randomized trial. Eur J Prev Cardiol. 2012 Oct;19(5):952-9. doi: 10.1177/2047487312450133. Epub 2012 Jun 11. PMID: 22689417.

    3 Arora RR, Chou TM, Jain D, Fleishman B, Crawford L, McKiernan T, Nesto RW. The multicenter study of enhanced external counterpulsation (MUST-EECP): effect of EECP on exercise-induced myocardial ischemia and anginal episodes. J Am Coll Cardiol. 1999 Jun;33(7):1833-40. doi: 10.1016/s0735-1097(99)00140-0. PMID: 10362181.

    4Henry TD, Losordo DW, Traverse JH, Schatz RA, Jolicoeur EM, Schaer GL, Clare R, Chiswell K, White CJ, Fortuin FD, Kereiakes DJ, Zeiher AN, Sherman W, Hunt AS, and Povsic TJ. Autologous CD34 cell therapy improves exercise capacity, angina frequency and reduces mortality in no-option refractory angina: a patient-level pooled analysis of randomized double-blinded trials, European Heart Journal, 2018.

    Forward Looking Statements:

    This press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements may include, among other things, statements relating to the continued development and cost of BioCardia’s autologous cell-based therapies, the probability of success of the CardiAMP clinical trials, ability to offset clinical costs utilizing Medicare reimbursement and the ultimate success of our clinical cell therapy programs. These forward-looking statements are made as of the date of this press release.

    We may use terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from the forward-looking statements contained in this press release. Factors that could cause or contribute to such differences include, but are not limited to, the Company’s liquidity position and its ability to raise additional funds, as well as the Company’s ability to successfully advance its clinical trials. As a result of these factors, we cannot assure you that the forward-looking statements in this press release will prove to be accurate. Additional factors that could materially affect actual results can be found in BioCardia’s Form 10-K filed with the Securities and Exchange Commission on March 26, 2025, under the caption titled “Risk Factors,” and in our subsequently filed Quarterly Reports on Form 10-Q. BioCardia expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

    MEDIA CONTACT:
    Miranda Peto, Investor Relations
    mpeto@biocardia.com
    (650) 226-0120

    INVESTOR CONTACT:
    David McClung, Chief Financial Officer
    investors@biocardia.com
    (650) 226-0120

    Continue Reading

  • Global Water Stress; Energy Running AI; and Automakers Navigate Tariffs – S&P Global

    1. Global Water Stress; Energy Running AI; and Automakers Navigate Tariffs  S&P Global
    2. Arizona Corporation Commission is considering utility rates just for data centers. It could take more than a year to implement  KJZZ
    3. Data centers’ water consumption raises concerns amid AI boom  Aaj English TV
    4. Data center boom raises concerns over power and water demand  Bond Buyer
    5. Phoenix Grapples with Data Center Expansion Amid Economic Promise and  Hoodline

    Continue Reading

  • Gaza hit by telecoms blackout as Israeli tanks advance

    Gaza hit by telecoms blackout as Israeli tanks advance


    KHAN YOUNIS: Exhaustion, despair and anger are grinding away at Ne’man Abu Jarad. Once again, for the 11th time, he and his family have been forced to uproot and move across the Gaza Strip.

    “It’s a renewal of the torture. We’re not being displaced, we’re dying,” Ne’man said last week as the family packed up their possessions and tents in Gaza City to escape escalating Israel bombardment ahead of a planned invasion of the city.

    The next day, they unpacked in southern Gaza on barren former agricultural land outside the city of Khan Younis, unsure where they would now find food and water.

    This has been the Abu Jarads’ life for nearly two years, since fleeing their home in the far north of Gaza days after Israel launched its onslaught in response to Hamas’ Oct. 7, 2023, attack. Like countless Palestinian families, they have fled the length of Gaza and back, forced to move every few months as Israel attacks each new shelter. The Associated Press has chronicled much of their journey.

    During the ceasefire that began in January, they had a bittersweet return to their home, which was damaged but still standing. But within two months, Israel broke the ceasefire, and the Abu Jarads had to wrench themselves away.

    With each move, Ne’man and his wife Majida try to preserve some stability for their six daughters and their 2-year-old granddaughter amid the misery of tent life. The youngest is 8-year-old Lana; the eldest is Balsam, in her 20s and married.

    But the sense of futility is weighing heavier. No end is in sight and Ne’man fears it will get worse.

    “What’s coming is dark,” he said. “We might be expelled (from Gaza). We might die … You feel like death is surrounding you. We just scurry from place to place, away from death.”

    Uprooted yet again

    “It gets worse for the girls. It’s hard on them to change every time they get used to something,” Majida said.

    Since May, the family’s refuge had been a tent in Gaza City. It wasn’t easy, but at least they got to know the neighborhood and their neighbors and figured out where to get water and medical care.

    Their daughters could see friends from before the war, who were also displaced nearby. Another family in a neighboring building let their daughter Sarah come use their Internet to study for online high school classes. The girls downloaded books onto their phones, to study or just to have something to do.

    Food was more difficult, as Israeli restrictions on aid pushed Gaza City into famine. Ne’man joined hundreds of others waiting for aid trucks to enter from Israel. It was dangerous – Israeli troops regularly opened fire toward the crowds, and Ne’man saw people getting killed and wounded, Majida said. But he sometimes came back with food.

    A few weeks ago, they found a school for Lana. “She was very excited. Her life would have some regularity,” Majida said.

    But Israel had ordered the population to evacuate, preparing a new assault to seize Gaza City that it said aims to dismantle Hamas, free hostages and move toward taking security control of the strip. Bombardment came closer. One strike leveled an apartment tower a block away, sending shrapnel that pierced the Abu Jarads’ tent. Another destroyed a house across the street, killing members of the family sitting outside, Ne’man said.

    Lana had only attended three days of classes. But it was time to go. Last Thursday, they joined a growing exodus of Palestinians fleeing south.

    Stress tears at the family

    Dressed in pink pajamas and leaning against her father in their new camp the next day, Lana described her best friends Sila and Joudi bidding her farewell as they left Gaza City. They hugged her and told her they loved her — and they were crying, Lana said.

    “But I did not cry,” she added firmly. “I will not cry at all. I won’t be sad.”

    Majida and Ne’man worry about Lana. Their other daughters had a grounding of normal lives. But Lana was only six when Israel’s campaign overturned their lives.

    “She is gaining awareness in the middle of war, bombardment and life in the tents,” Majida said.

    Lana can be stubborn and impatient.

    “There’s things my sisters put up with that I don’t put up with,” Lana said. She can’t tolerate the discomforts of tent life. Having to use the makeshift bathroom upsets her. “Sitting and reading, I can’t get comfortable,” she said.

    Over the months, everything pushes the family to a boil — boredom, lack of privacy, the daily toil of lugging water, gathering firewood, searching for food, cleaning the tent. Behind that lie darker thoughts: the feeling this could be their fate forever, the fear a strike could kill them.

    Crammed together in the tent, the girls squabble and fight sometimes.

    “We were a model family, understanding and loving,” Ne’man said. “I never imagined we’d reach this point. I get afraid the family will fragment from all the pressure.”

    ‘In a desert’

    The latest move drained what little money they had — hundreds of dollars to buy a new tent and rent a truck to carry their belongings.

    It also stripped them of everything that made life bearable. The new camp lies in a stretch of barren dirt and fields. There’s no market nearby, no schools. They have to walk 2 kilometers (1.2 miles) to get an Internet connection. They are surrounded by strangers.

    “We’re living in a desert,” Ne’man said.

    Friday morning, their daughters walked more than a kilometer (half mile) to catch up with a passing water truck. It ran out before they could fill all their plastic jugs.

    The family spent the day clearing their spot of land, assembling their two tents — one for the family, one for Ne’man’s sister. As they worked, an Israeli strike rang out in the distance. They watched the black smoke rise over Khan Younis. Exhausted by the end of the day, Ne’man still had to dig a latrine and set up the bathroom.

    The area had been a closed Israeli military zone until a few weeks ago, when Israel announced displaced could move there. An Israeli military position is not far away. They can see tanks moving in and out.

    “It’s not safe here,” Ne’man said.

    Majida tried to focus on practicalities.

    If someday water trucks start coming closer, she said, the girls won’t have to walk as far and will grumble less. Once they set aside a corner for a kitchen, where they can cook and do washing, that will start creating a daily routine.

    “The more details of daily life that are in place, the more comfortable we will feel,” Majida said.

    “Things will get better,” she said again and again, without a trace of optimism in her voice.

    They may have to move again

    Four days later, on Tuesday, a voice message from Ne’man came to the AP.

    “We’re sitting here unable to eat,” he said. They have almost no money to buy food. No aid is reaching them.

    Worse, a man claiming to be the owner of the land had come, backed by armed men, and demanded they pay rent or leave. Ne’man can’t afford rent. He can’t afford the costs of moving, but may have no choice.

    “Soon we’ll die of starvation,” he said. “Two years, all our energy has been drained, physically, mentally, financially. We can’t bear more than this.”

    Continue Reading

  • ‘Triple conjunction’ 2025: See the moon, Venus and the bright star Regulus in an ultraclose alignment in the sky tomorrow

    ‘Triple conjunction’ 2025: See the moon, Venus and the bright star Regulus in an ultraclose alignment in the sky tomorrow

    One of the best naked-eye stargazing sights of the year is on offer to skywatchers this week — if you can rise before the sun Friday (Sept. 19). Just before sunrise, the crescent moon, the brilliant planet Venus and the bright star Regulus (the brightest star in the constellation Leo) will cluster together on the east-northeast horizon.

    There will be barely half a degree between each of the three objects, which is less than the width of a little finger held up against the sky. This triple conjunction of naked-eye objects is a rare sight worth trying to see.

    Continue Reading

  • Who are the favourites as Formula 1 heads to the streets of Baku for the 2025 Azerbaijan Grand Prix?

    Who are the favourites as Formula 1 heads to the streets of Baku for the 2025 Azerbaijan Grand Prix?

    Formula 1 heads to the streets of Baku this weekend as the season enters its latter stages, but who are the favourites to come out on top? Here are what the odds tell us…

    Odds are provided by F1’s Official Betting Data Supplier ALT Sports Data, are subject to change and are presented in decimal form: for every $1 wagered you would win the figure represented by the odds; so, if Verstappen is favourite at 1.50, you would win $1.50 for every dollar bet.

    THE ODDS FOR THE WIN

    Baku was the location of Oscar Piastri’s second-ever F1 victory just 12 months ago, and since then, the Australian has bagged seven wins, averaging 2.38 across this campaign. He leads the 2025 Drivers’ Championship by 31 points from McLaren team mate, Lando Norris. The Briton bounced back at Monza after failing to finish the Dutch Grand Prix but has clinched top honours in four out of the last nine races.

    Four-time World Champion Max Verstappen arrives in Eurasia fresh off his third trip to the top step of the podium this season. The low downforce at Monza suited his Red Bull, and he’ll be backing his chances coming into this weekend. However, a twisty middle sector to the lap may complicate car set-up.

    THE ODDS FOR A PODIUM FINISH

    Charles Leclerc has been Ferrari’s top-performing driver this year and just missed out on the champagne celebrations in Italy, finishing fourth. The Monegasque has reached the chequered flag inside the top three spots on five occasions this year and will be desperate to go one better on the streets of Baku this year after finishing runner-up in 2024.

    Mercedes’ top dog, George Russell, last stood on the rostrum in Hungary and carries six podiums with him into this weekend at a venue where he has finished on the rostrum twice in three years.

    THE ODDS FOR A TOP-SIX FINISH

    The season has proven arduous for seven-time World Champion Lewis Hamilton, who has failed to clinch a top-three yet and has only achieved a top-six result in 50% of his starts. His best return is fourth place, which he’s achieved in three races.

    Alex Albon continues to threaten the top-six places, with five to his name this campaign, but he just missed out at Monza, finishing seventh. Fernando Alonso, meanwhile, will look to bounce back from retirement at Monza when running strong.

    THE ODDS FOR A TOP-10 FINISH

    Rookie Gabriel Bortoleto is a prime candidate for a top-10 finish in Azerbaijan. The Brazilian has come into his own since Austria, scoring four top-10 finishes since F1 visited the Red Bull Ring. He crossed the line in eighth two weeks ago.

    Another youngster making a habit of top-10 performances is Isack Hadjar, who backed up his rostrum in the Netherlands with a top-10 at Monza, his seventh such result of the season.

    Kimi Antonelli has blown hot and cold in recent rounds but held his nerve to claim ninth in Italy on home soil, while Liam Lawson caps off our picks in this department, boasting a 50% top-10 return in his previous six appearances.

    THE ODDS FOR WHO WILL BE FASTEST IN QUALIFYING

    After snatching pole position in Italy, Max Verstappen tied Oscar Piastri for most front-row starts this year. The duo sit on five apiece, followed by Lando Norris, who has stopped the clock the quickest in four Saturday sessions in 2025.

    Fast straights and low downforce will suit the RB21, so don’t be surprised if Verstappen rises with the quickest time on Saturday afternoon. However, he’ll have to dethrone Charles Leclerc, who has started from pole position in the last four Azerbaijan Grands Prix.

    THE ODDS FOR THE WINNING CONSTRUCTOR

    Red Bull sets up shop for the weekend with the best record in Baku of any Formula 1 team. The Milton Keynes team has taken the trophy in four of the last seven races.

    Mercedes own three victories on this track, but none in the post-covid era, while McLaren sit with a lone triumph. The Woking establishment took the chequered flag on their last visit courtesy of Oscar Piastri, and sit on the cusp of the Teams’ Championship this weekend.

    Continue Reading

  • Cervical cancer survivors may benefit from anal screening – springermedicine.com

    1. Cervical cancer survivors may benefit from anal screening  springermedicine.com
    2. Cervical cancer survivors may face higher risk of anal cancer  Times of India
    3. Haluk Damgacioglu, PhD, discusses cervical cancer’s link to anal cancer risk  Contemporary OB/GYN
    4. Consider Anal Cancer Screening in Some Older Women, Study Says  MedPage Today
    5. Cervical Cancer Survivors Have Higher Risk of Another Type Of Cancer  The Herald Palladium

    Continue Reading

  • Leonardo DiCaprio on why his new film addresses ‘divisiveness in our culture’

    Leonardo DiCaprio on why his new film addresses ‘divisiveness in our culture’

    Yasmin RufoCulture reporter

    Getty Images Leonardo DiCaprio attends the "One Battle After Another" London Premiere at Odeon Luxe Leicester Square on September 16, 2025 in London, EnglandGetty Images

    The Oscar-winning actor spoke to the BBC about the political message of his new film

    One Battle After Another, the film starring Leonardo DiCaprio, Benicio del Toro and Sean Penn, has been 20 years in the making, according to its filmmaker Paul Thomas Anderson.

    DiCaprio stars as Bob, a paranoid ex-revolutionary living off-grid, who reunites with former accomplices as he’s forced to confront an old nemesis after his daughter goes missing.

    Director Anderson came up with the idea for the film, which also stars Teyana Taylor and Regina Hall, more than two decades ago, loosely inspired by Thomas Pynchon’s 1990 novel Vineland.

    DiCaprio, who won an Oscar in 2016 for survival epic The Revenant, told the BBC the film reflects what he sees as the growing polarisation in society.

    “It holds a mirror up to society and talks about the divisiveness in our culture and the fact that there’s so much polarity.”

    The Wolf of Wall Street actor explained that while he doesn’t feel like there’s a central message to the film, “there’s an interesting undercurrent about extremism”.

    “It’s political without making it feel like medicine,” he adds.

    Warner Bros Leonardo DiCaprio as Bob in One Battle After Another standing outside a car holding a gun Warner Bros

    Critics have praised DiCaprio’s performance as an ex-revolutionary who confronts an old nemesis

    The Usual Suspects actor del Toro plays martial arts instructor Sergio, who comes to Bob’s help when he’s under threat.

    He explains that the film “says something about its time” but “it’s also entertaining, fun and has a lot of heart”.

    Del Toro was most excited about having been able to work with DiCaprio, who he has “admired and wanted to work with for many years”.

    “Leo and I are from the same class if Hollywood was a university – I’ve met him many times and then finally we got a chance to work together.

    “It’s a dream come true and he’s very funny in real life and in the movie.”

    Getty Images L-R) Benicio del Toro, Chase Infiniti, Leonardo DiCaprio, Teyana Taylor and Sean Penn attend the London Premiere of "One Battle After Another" at Leicester Square on September 16, 2025 in London, England.Getty Images

    Starring alongside DiCaprio is Benicio del Toro, Chase Infiniti, Teyana Taylor and Sean Penn

    One Battle After Another is part political satire, part black comedy and part action blockbuster, and DiCaprio says overall the film “finds the humanity in all the central characters”.

    “It’s about the people in the film and the characters – I’m a flawed protagonist – you can relate to them and their struggles and that’s not an easy thing to do.”

    The Titanic star previously told Entertainment Tonight his character is the opposite of Tom Cruise in Mission: Impossible as Bob “does everything wrong and doesn’t land or stick any of his stunts”.

    ‘Surefire Oscar frontrunner’

    The Times’s Kevin Maher awarded the film four-stars, calling it a “career high” for Shutter Island actor DiCaprio, adding the film is “a surefire Oscar frontrunner”.

    Maher said Anderson, operating with an alleged budget of $175m, was working on “his most ambitious canvas” and concluded the film has an “easy best picture Oscar nomination in the bag”.

    DiCaprio said that Anderson has “done a lot of films but in this one, he really went for it”.

    Anderson also directed 2017’s Phantom Thread and 2007’s There Will Be Blood, both of which won Oscars.

    Praising the filmmaker, DiCaprio called him “a visionary and seminal director”.

    Continue Reading

  • Qnity Electronics, Inc. to Host 2025 Investor Day on September 18, 2025 at 2:00pm ET

    *On January 15, 2025, DuPont announced it is targeting November 1, 2025, for the completion of the Spin-Off. The Spin-Off will not require a shareholder vote and is subject to satisfaction of customary conditions, including final approval by DuPont’s board of directors, receipt of tax opinion from counsel, the completion and effectiveness of the Form 10 registration statement filed with the SEC, applicable regulatory approvals and satisfactory completion of financing.

     

    Cautionary Statement Regarding Forward-Looking Statements

    This release contains forward-looking statements. Forward-looking statements use words such as “plans”, “expects”, “will”, “would”, “anticipates”, “believes”, “intends”, “seeks”, “projects”, “efforts”, “estimates”, “potential”, “continue”, “intend”, “may”, “could”, “should” and similar expressions, among others, as well as other words or expressions referencing future events, conditions or circumstances. Statements that describe or relate to DuPont’s or Qnity’s plans, goals, intentions, strategies, financial estimates, DuPont’s or Qnity’s expectations regarding the Spin-Off, and statements that do not relate to historical or current fact, are examples of forward-looking statements. Forward-looking statements are based on our current beliefs, expectations and assumptions, which may not prove to be accurate, and involve a number of known and unknown risks and uncertainties, many of which are out of DuPont’s and Qnity’s control. Forward-looking statements are not guarantees of future performance, and there are a number of important factors that could cause actual outcomes and results to differ materially from the results contemplated by such forward-looking statements. Additional information concerning these and other factors can be found in DuPont’s and Qnity’s filings with the U.S. Securities and Exchange Commission, including DuPont’s most recent annual report on Form 10-K, most recent quarterly report on Form 10-Q and current reports on Form 8-K and Qnity’s registration statement on Form 10. Any forward-looking statement speaks only as of the date on which it is made. Neither DuPont nor Qnity undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

    Continue Reading

  • Oldest and most complete fossil of a dome-headed dinosaur is found in Mongolia

    Oldest and most complete fossil of a dome-headed dinosaur is found in Mongolia

    Scientists have unearthed in Mongolia the oldest and most complete fossil of a pachycephalosaur, a group of dinosaurs known for their dome-shaped skulls, according to a new study published Wednesday in the journal Nature.

    The fossil, which dates back between 108 and 115 million years, belongs to a juvenile from a previously unknown species that researchers are calling Zavacephale rinpoche.

    It was discovered in the Khuren Dukh formation in the Gobi Desert in Mongolia, a landlocked nation between China and Russia, by a team led by paleontologist Tsogtbaatar Chinzorig of the Mongolian Academy of Sciences.

    Very little is known about pachycephalosaurs, two-legged herbivores that lived in Asia and North America during the Cretaceous Period and are among the “most enigmatic” dinosaurs, the study said. They have become an object of growing popular fascination thanks to their distinctive, bony skulls as well as appearances in media such as the Jurassic Park films.

    Previously discovered pachycephalosaur fossils were mostly limited to skulls.

    “You could fit all of the pachycephalosaurs [fossils] in the world within a bathtub, more or less, or maybe two bathtubs — there are very few fossil pachycephalosaurs,” Michael Pittman, a paleobiologist from the Chinese University of Hong Kong, told NBC News.

    The Mongolia discovery is the “most skeletally complete,” the study said, providing researchers with far more detail about the anatomy of pachycephalosaurs than they had before.

    Researchers said the Zavacephale individual they found was at least 2 years old and about 3 feet long. Its skeleton, more than half of which has been found, features long legs, short arms and small hands, as well as stones known as gastroliths that the animal would have swallowed to help grind down the vegetation that it ate.

    Though the animal was not fully grown, its skeleton also already had the pachycephalosaur’s signature thickened bone on top of the skull.

    The completeness of the fossil “makes it an important specimen for understanding how the cranial dome of pachycephalosaur developed,” Chinzorig told the National History Museum in London.

    The purpose of the dome remains unclear, though scientists have suggested pachycephalosaurs may have used them to butt heads in combat or to impress potential mates.

    The fossil is also about 15 million years older than previously discovered pachycephalosaur specimens, helping to shed light on how the dinosaurs evolved.

    “It’s the oldest pachycephalosaur, so it’s giving us information of what earlier species were like and how they changed through time,” Pittman said. “So finding an earlier one that still has it shows that actually they’ve had that dome for a long time.”

    Zavacephale was smaller than later pachycephalosaurs, which could grow to about 14 feet long.

    Continue Reading

  • Stock market rises for 3rd consecutive day on US Fed rate cut, buying in IT sector

    Stock market rises for 3rd consecutive day on US Fed rate cut, buying in IT sector

    MUMBAI: The Indian equity indices extended the gaining momentum for the third consecutive session on Thursday amid buying in IT stocks after the US Fed announced a rate cut.

    Sensex closed at 83, 013.96, up 320.25 points or 0.39 per cent.

    The 30-share index opened with a decent gap-up at 83, 108.92 against the last session’s closing of 82, 693.71 after the US Fed announced a rate cut. However, the index remained range-bound throughout the session amid a mixed approach across sectors except IT.

    Nifty ended the session at 25, 423.60, up 93.35 points or 0.37 per cent.

    “Global equities traded in the green after the U.S. Federal Reserve cut rates by 25 bps to 4–4.25 per cent and signalled two more reductions this year to cushion rising job market risks. Mirroring the upbeat global sentiment, Indian markets opened with a positive gap-up and maintained a sideways trajectory through the first half of the session, ” Ashika Institutional Equities said in a note.

    Eternal, Sun Pharma, Infosys, HDFC Bank, PowerGrid, HCL Tech, ITC, Hindustan Unilever, Tata Steel, Axis Bank and Bajaj FinServ settled high amid the Sensex stocks. Bajaj Finance, Tata Motors, Trent, Ultratech Cement, and Asian Paints ended the session in negative territory.

    The majority of sectoral indices remained in green amid value buying. Nifty Fin Services jumped 135 points or 0.51 per cent, Nifty Bank rose 234 points or 0.42 per cent, Nifty Auto moved up 34 points or 0.13 per cent, Nifty FMCG jumped up 201 points or 0.36 per cent, and Nifty IT surged 303 points or 0.83 per cent.

    Broader indices continued their bullish run amid buying in midcap and small-cap stocks. Nifty Small Cap 100 jumped 53 points or 0.29 per cent, Nifty Midcap 100 increased 224 points or 0.38 per cent, and Nifty 100 ended the session 91 points or 0.35 per cent high.

    Continue Reading